<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><?release-delay 0|0?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Oncol. Rep</journal-id><journal-title-group><journal-title>Oncology Reports</journal-title></journal-title-group><issn pub-type="ppub">1021-335X</issn><issn pub-type="epub">1791-2431</issn><publisher><publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3783056</article-id><article-id pub-id-type="doi">10.3892/or.2013.2594</article-id><article-id pub-id-type="publisher-id">or-30-03-1053</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>ARAKAWA</surname><given-names>YASUHIRO</given-names></name><xref ref-type="aff" rid="af1-or-30-03-1053">1</xref><xref ref-type="corresp" rid="c1-or-30-03-1053"/></contrib><contrib contrib-type="author"><name><surname>OZAKI</surname><given-names>KOJI</given-names></name><xref ref-type="aff" rid="af2-or-30-03-1053">2</xref></contrib><contrib contrib-type="author"><name><surname>OKAWA</surname><given-names>YUTAKA</given-names></name><xref ref-type="aff" rid="af3-or-30-03-1053">3</xref></contrib><contrib contrib-type="author"><name><surname>YAMADA</surname><given-names>HISASHI</given-names></name><xref ref-type="aff" rid="af2-or-30-03-1053">2</xref></contrib></contrib-group><aff id="af1-or-30-03-1053"><label>1</label>Department of Oncology and Hematology, Jikei University School of Medicine, Minato-Ku, Tokyo 105-8471, Japan</aff><aff id="af2-or-30-03-1053"><label>2</label>Department of Molecular Genetics, Jikei University School of Medicine, Minato-Ku, Tokyo 105-8471, Japan</aff><aff id="af3-or-30-03-1053"><label>3</label>Department of Internal Medicine, Sasaki Hospital, Fukaya, Saitama 366-0824, Japan</aff><author-notes><corresp id="c1-or-30-03-1053">Correspondence to: Dr Yasuhiro Arakawa, Department of Oncology and Hematology, Jikei University School of Medicine, Nishi-Shimbashi 3-19-18, Minato-Ku, Tokyo 105-8471, Japan, E-mail: <email>yarakawa@jikei.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>05</day><month>7</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>05</day><month>7</month><year>2013</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>30</volume><issue>3</issue><fpage>1053</fpage><lpage>1058</lpage><history><date date-type="received"><day>01</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>21</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013, Spandidos Publications</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p>This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.</license-p></license></permissions><abstract><p>Various anticancer drugs, including camptothecins and indolocarbazoles, target DNA topoisomerase I (Top1). We previously described the camptothecin-resistant colon cancer cell line DLDSNR6, which has a Gly365Ser missense mutation in Top1. In the present study, we established highly camptothecin-resistant sublines from DLDSNR6 cells by continuous exposure to higher camptothecin concentrations. The established sublines grew in the presence of 30 &#x003bc;M of camptothecin, but exhibited markedly retarded growth. In addition to Gly365Ser, these sublines harbored a Top1 Gly717Arg mutation and some had also a Top1 Gln421Arg mutation. Top1 activity was reduced to approximately one-eighth in highly resistant cell lines compared with that in parental DLD-1 cells. Resistant clones with 3 Top1 mutations including Gln421RArg exhibited the highest resistance to the indolocarbazole J-107088 in terms of the effect on the cell cycle distribution. The Gln421 mutation was equivalent to a mutation recently found in camptothecin biosynthesizing plants, but it has not previously been found in mammalian cells.</p></abstract><kwd-group><kwd>DNA topoisomerase I</kwd><kwd>camptothecin resistance</kwd><kwd>indolocarbazole resistance</kwd><kwd>colorectal cancer</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>DNA topoisomerase I (Top1) is an essential enzyme in higher eukaryotes as well as the prime intracellular target of various classes of anticancer drugs, such as camptothecins, indenoisoquinolines and indolocarbazoles (<xref rid="b1-or-30-03-1053" ref-type="bibr">1</xref>&#x02013;<xref rid="b3-or-30-03-1053" ref-type="bibr">3</xref>). Top1 catalyzes the relaxation of DNA supercoiling to allow the processes of replication, transcription, and recombination to occur by reversibly nicking one strand and forming transient DNA cleavage complexes (<xref rid="b4-or-30-03-1053" ref-type="bibr">4</xref>). Under physiological conditions, cleavage complexes are transient. Top1-targeting drugs, which act as &#x02018;interfacial inhibitors&#x02019;, stabilize covalent Top1-DNA complexes and cause DNA strand breaks that lead to the apoptosis of drug-treated cells (<xref rid="b5-or-30-03-1053" ref-type="bibr">5</xref>).</p><p>The underlying mechanisms of the resistance to Top1-targeting drugs may involve the inappropriate accumulation of drug in the tumor cells, mutations in Top1, or changes in the cellular response to DNA strand breaks. Mutations of Top1 that give culture cells resistance to Top1-targeting drugs have been identified (<xref rid="b6-or-30-03-1053" ref-type="bibr">6</xref>). We previously established a camptothecin-resistant colon cancer cell line, which was designated DLDSNR6, and identified a missense mutation of the Top1 gene that resulted in a glycine to serine substitution at codon 365. In these resistant cells, Top1 shows lower catalytic activity and camptothecin traps fewer Top1-DNA complexes than parent DLD-1 cells (<xref rid="b7-or-30-03-1053" ref-type="bibr">7</xref>).</p><p>Camptothecin is a plant alkaloid produced by the Chinese tree <italic>Camptotheca acuminata</italic>. Camptothecin and its derivatives are potent poisons to most eukaryotic cells, including those of higher plants, but camptothecin-producing trees are insensitive to these self-producing toxic metabolites. Sirikantaramas <italic>et al</italic>(<xref rid="b8-or-30-03-1053" ref-type="bibr">8</xref>) demonstrated that camptothecin-producing plants have point mutations in the Top1 gene at Asn421, Leu530 and Asn722, which confer resistance to camptothecins. Although Top1 mutations at codon 722 have been identified in several camptothecin-resistant human cancer cell lines, the other mutations have yet to be found (<xref rid="b9-or-30-03-1053" ref-type="bibr">9</xref>).</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Materials</title><p>SN-38 was kindly provided by Yakult Co., Ltd. (Tokyo, Japan), and J-107088 was kindly supplied by MSD K.K. (Tokyo, Japan, formerly Banyu Pharmaceutical Co., Ltd). Other chemicals were purchased from Sigma-Aldrich Japan K.K. (Tokyo, Japan). SN-38, J-107088, camptothecin and Ko143 were resuspended with Me<sub>2</sub>SO as stock solutions and stored at &#x02212;20&#x000ba;C. Verapamil was resuspended with water and stored at &#x02212;20&#x000ba;C. Rabbit anti-Top1 antibody was purchased from TopoGEN, Inc. (Columbus, OH, USA), and mouse anti-DNA topoisomerase II &#x003b1; (Top2&#x003b1;) antibody was purchased from Medical &#x00026; Biological Laboratories Co., Ltd. (Nagoya, Japan).</p></sec><sec><title>Establishment of highly camptothecin-resistant colon cancer cell sublines</title><p>The DLD-1 human colon cancer cell line was provided by the Cell Resource Center for Biochemical Research of Tohoku University (Sendai, Japan). We previously established the DLDSNR6 cell line from parental DLD-1 cells through the continuous exposure to stepwise increases in SN-38 concentrations (<xref rid="b7-or-30-03-1053" ref-type="bibr">7</xref>). In this study, DLDSNR6 cells were exposed to stepwise increases in camptothecin concentrations (up to 2 &#x003bc;M) over a period of 4 months and then SNRA23F and SNRA311E sublines were established by the limiting dilution technique. The camptothecin-resistant cell pool was again exposed to camptothecin with concentrations up to 10 &#x003bc;M for 3 months, and SNRD16F and SNRD38F sublines were obtained (<xref rid="f1-or-30-03-1053" ref-type="fig">Fig. 1A</xref>). These cell lines were cultured at 37&#x000ba;C in RPMI-1640 medium (Life Technologies Japan, Tokyo, Japan) that was supplemented with 10% fetal bovine serum (Thermo Fisher Scientific K.K., Yokohama, Japan) and Antibiotic-Antimycotic Mixed Solution (Nacalai Tesque, Inc., Kyoto, Japan) under a humidified atmosphere containing 5% CO<sub>2</sub>.</p></sec><sec><title>Cell growth, viability and cytotoxicity assays</title><p>DLD-1, DLDSNR6, SNRA23F, SNRA311E, SNRD16F and SNRD38F cells (5.0&#x000d7;10<sup>5</sup>/ml) were cultured in 6-cm culture dishes for 48&#x02013;72 h. The number of viable cells was counted by the trypan blue dye exclusion method with a hemocytometer. The cytotoxicity of Top1-targeting drugs was measured by an MTS assay (Cell Titer 96 Aqueous One Solution Cell Proliferation Assay; Promega, San Luis Obispo, CA, USA) with minor technical modifications. Three to ten thousand cells were incubated in a 96-well tissue culture plate for 96 h in the presence of the indicated concentrations of camptothecin, SN-38, and J-107088, after which the assay was performed according to the manufacturer's instructions. All the experiments were performed in triplicate.</p></sec><sec><title>Detection of Top1 mutations</title><p>Total RNA was extracted from each cell line and reverse transcription was performed. The full-length Top1 cDNA was amplified by polymerase chain reaction (PCR), and the resulting fragments were inserted into the cloning vector. The entire Top1 open reading frame was sequenced with the BigDye Terminator Version 3.1 Cycle Sequencing kit (Life Technologies Japan) and the ABI 3700 DNA Analyzer (<xref rid="b7-or-30-03-1053" ref-type="bibr">7</xref>,<xref rid="b10-or-30-03-1053" ref-type="bibr">10</xref>).</p></sec><sec><title>Preparation of protein samples and immunoblotting analysis</title><p>Crude cell extracts were prepared by suspending the cells in radioimmunoprecipitation assay lysis buffer containing 1 &#x003bc;M phenylmethylsulfonyl fluoride, and the protein concentrations of each sample were measured by the Bradford method. Protein samples were separated by 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting was performed with antibodies for Top1 and Top2&#x003b1;.</p></sec><sec><title>Top1-mediated DNA relaxation assay</title><p>The Top1 catalytic activities of the nuclear extracts from each cell line were determined by measuring the relaxation of the supercoiled pHOT1 plasmid (TopoGEN, Inc.), which contained a Top1-cleavage site that was derived from the tetrahymena ribosomal gene repeat (<xref rid="b11-or-30-03-1053" ref-type="bibr">11</xref>). The supercoiled pHOT1 plasmid (0.25 &#x003bc;g) was incubated with the indicated amounts of nuclear extracts in 10 mM Tris-HCl (pH 7.5), 150 mM NaCl, and 1 mM ethylenediaminetetraacetic acid (EDTA) at 37&#x000ba;C for 60 min in a final volume of 20 &#x003bc;l (<xref rid="b7-or-30-03-1053" ref-type="bibr">7</xref>). The reaction was terminated by the addition of 5 &#x003bc;l of 0.05% sodium dodecyl sulfate and the samples were loaded onto 1% agarose gels. After electrophoresis, the gels were stained with Tris-borate EDTA buffer (89 mM Tris-borate, 2 mM EDTA, pH 8.0) containing 0.5 &#x003bc;g/ml ethidium bromide and visualized by transillumination with UV light. Relaxation activity was identified by the disappearance of the supercoiled DNA.</p></sec><sec><title>Quantitative reverse transcription (qRT)-PCR array analysis of ATP-binding cassette transporters</title><p>To assess the relative expression of ATP-binding cassette transporters in each cell line, we used the TaqMan&#x02122; Array Gene Signature 96-well plates (human ABC transporters; Life Technologies Japan). After 2 months of passage in drug-free medium, the cells were harvested, and the total RNA was extracted with ISOGEN reagent (Nippon Gene, Tokyo, Japan). The analysis was performed according to the manufacturer's directions with the Applied Biosystems 7500 Real-Time PCR system (Life Technologies Japan). As a measure of the relative levels of expression between the parental DLD-1 and the resistant cell lines, &#x00394;&#x00394;Ct values were calculated and converted to fold-change values (2<sup>&#x02212;&#x00394;&#x00394;Ct</sup>).</p></sec><sec><title>Flow cytometry</title><p>The effects of J-107088 on cell cycle distribution in each cell line were determined with propidium iodide staining and analyzed with flow cytometry. Each cell line was either treated with vehicle alone [Me<sub>2</sub>SO (0.2%)], J-107088 (5 &#x003bc;M), J-107088 (5 &#x003bc;M) plus verapamil (10 &#x003bc;M), or J-107088 (5 &#x003bc;M) plus Ko143 (0.3 &#x003bc;M) for 48 h. Cells were harvested, fixed in 70% precooled ethanol, and incubated in phosphate-buffered saline containing 10 &#x003bc;g/ml propidium iodide and 10 &#x003bc;g/ml RNase for 30 min at room temperature. The fluorescence (excitation at 488 nm and emission at 585/42 nm) of 2&#x000d7;10<sup>4</sup> cells from each sample was analyzed with FACSCalibur (Becton-Dickinson, San Jose, CA, USA) flow cytometry, and the cell population at each cell cycle phase was determined with ModiFit software (Becton-Dickinson).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Establishment of highly camptothecin-resistant colon cancer cells</title><p>In this study, we established the SNRA23F, SNRA311E, SNRD16F and SNRD38F sublines, which were highly camptothecin-resistant cell lines (<xref rid="f1-or-30-03-1053" ref-type="fig">Fig. 1A</xref>). These cells exhibited markedly retarded growth compared with that of parental DLD-1 and DLDSNR6 cells (<xref rid="f1-or-30-03-1053" ref-type="fig">Fig. 1B</xref>). Observations of the cells stained with 4&#x02032;-6-diamidino-phenylindole under a fluorescence microscope revealed no signs of apoptotic cell death in the resistant cell lines (data not shown). The newly established sublines grew in the presence of 30 &#x003bc;M of camptothecin. In addition, these cells were resistant to the indolocarbazole derivative, J-107088 (<xref rid="f2-or-30-03-1053" ref-type="fig">Fig. 2</xref>).</p></sec><sec><title>Three missense mutations of the Top1 gene in resistant cell lines</title><p>We previously identified a Top1 missense mutation in DLDSNR6 cells at codon 365, which resulted in the amino acid alteration of glycine (GGC) to serine (AGC) (<xref rid="b7-or-30-03-1053" ref-type="bibr">7</xref>). In addition, the parental DLD-1 cells had a heterozygous Top1 missense mutation resulting in a Met675Ile alteration (<xref rid="b12-or-30-03-1053" ref-type="bibr">12</xref>,<xref rid="b13-or-30-03-1053" ref-type="bibr">13</xref>). The highly camptothecin-resistant cells (SNRA23F, SNRA311E, SNRD16F and SNRD38F) harbored a Top1 missense mutation at codon 717, which resulted in a glycine (GGA) to arginine (AGA) substitution. Furthermore, the SNRD16F and SNRD38F cell lines carried a codon 421 mutation that resulted in the substitution from glutamine (CAA) to arginine (CGA) (<xref rid="f3-or-30-03-1053" ref-type="fig">Fig. 3</xref>).</p></sec><sec><title>Top1 protein expression and enzymatic function in resistant cell lines</title><p>There were slightly lower levels of Top1 protein expression in highly camptothecin-resistant cell lines compared with those of the parental DLD-1 and DLDSNR6 cells, whereas the levels of Top2 protein expression were increased in these sublines (<xref rid="f4-or-30-03-1053" ref-type="fig">Fig. 4A</xref>). The DNA relaxation assay revealed that Top1 activity was markedly reduced to approximately one-eighth in highly camptothecin-resistant cell lines compared with that in DLD-1 cells (<xref rid="f4-or-30-03-1053" ref-type="fig">Fig. 4B</xref>).</p></sec><sec><title>Expression of ATP-binding cassette transporters</title><p>The levels of mRNA expression of the ATP-binding cassette transporters ABCB1 [multidrug resistance protein 1 (MDR1)] and ABCG2 [breast cancer resistance protein (BCRP)] were significantly increased in camptothecin-resistant cell lines, including DLDSNR6. However, the levels of mRNA expression of ABCC2 (multidrug resistance-associated protein 2) were reduced in SNRA23F and SNRA311E cells (<xref rid="tI-or-30-03-1053" ref-type="table">Table I</xref>).</p></sec><sec><title>Cell cycle analysis of J-107088-treated cells</title><p>The flow cytometry analysis of untreated cells revealed that the S-phase fraction was not reduced in highly camptothecin-resistant cells (<xref rid="f5-or-30-03-1053" ref-type="fig">Fig. 5</xref>) compared with parental cells (~24% in DLD-1 cells, ~30% in DLDSNR6 cells, data not shown). When cells were treated with 5 &#x003bc;M of J-107088 for 48 h, accumulation was observed in the late S-G<sub>2</sub>/M phase in SNRA23F and SNRA311E cells, while the cell cycle distribution was not clearly affected in SNRD16F and SNRD38F cells (<xref rid="f5-or-30-03-1053" ref-type="fig">Fig. 5</xref>). Treatment with camptothecin at the higher concentration of 10 &#x003bc;M caused marginal changes in the cell cycle distribution in highly camptothecin-resistant cells (data not shown). The addition of the MDR1 inhibitor, verapamil, to 5 &#x003bc;M of J-107088 did not evidently affect the cell cycle distribution. When cells were coincubated with the BCRP inhibitor, Ko143, and 5 &#x003bc;M of J-107088 for 48 h, a marked accumulation in late S to G<sub>2</sub>/M phase was observed in all highly camptothecin-resistant cells, while the G<sub>0</sub>/<sub>1</sub> population was still observed in SNRD16F and SNRD38F cells (<xref rid="f5-or-30-03-1053" ref-type="fig">Fig. 5</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In the present study, we established highly camptothecin-resistant colon cancer cell lines and characterized these cells. First, the highly resistant clones (SNRA23F, SNRA311E, SNRD16F, and SNRD38F) were retarded in growth and showed slightly lower levels of Top1 protein expression (<xref rid="f1-or-30-03-1053" ref-type="fig">Fig. 1B</xref> and <xref rid="f4-or-30-03-1053" ref-type="fig">4A</xref>). The previously established DLDSNR6 cells exhibited a loss of heterozygosity in the Top1 gene, but these cells did not exhibit significant growth retardation. Toyoda <italic>et al</italic>(<xref rid="b14-or-30-03-1053" ref-type="bibr">14</xref>) demonstrated the heterozygous disruption of the Top1 gene in a human pre-B cell line, Nalm-6. The TOP1-heterozygous Nalm-6 cells exhibited ~70% protein expression levels of Top1, but they showed no significant differences in the growth rate compared with that of the parental cells. In our highly camptothecin-resistant cells, Top1 enzymatic activity levels were reduced to approximately one-eighth mainly due to the new missense mutations (<xref rid="f4-or-30-03-1053" ref-type="fig">Fig. 4B</xref>). The TOP1 wild-type allele was not expressed in our cells. Top1 knockdown that was conducted with small interfering RNA to the level of ~10&#x02013;20% in cancer cell lines caused genomic instability and replication defects (<xref rid="b15-or-30-03-1053" ref-type="bibr">15</xref>). Minor deficits in Top1 activity may not affect the cell growth rate. Human Top2&#x003b1;, which can relax the positively supercoiled DNA, has been shown to partially compensate for Top1 activity (<xref rid="b16-or-30-03-1053" ref-type="bibr">16</xref>). Our newly established resistant cells showed high levels of expression of Top2&#x003b1; (<xref rid="f4-or-30-03-1053" ref-type="fig">Fig. 4A</xref>). The increased levels of Top2&#x003b1; expression in these cells but not in DLDSNR6 cells may suggest that a substantial reduction of Top1 activity levels occurred only in highly resistant cells.</p><p>Our highly camptothecin-resistant clones grew in the presence of 30 &#x003bc;M of camptothecin (<xref rid="f2-or-30-03-1053" ref-type="fig">Fig. 2</xref>). These clones harbored two or three missense mutations in the Top1 gene. The X-ray structure of human Top1 has been determined (<xref rid="b17-or-30-03-1053" ref-type="bibr">17</xref>,<xref rid="b18-or-30-03-1053" ref-type="bibr">18</xref>), and it shows that the cap region (residues 215&#x02013;433) is sterically close to the catalytic Tyr723. When Top1 clamps double-stranded DNA, some loop regions focus on one side of the DNA (<xref rid="b17-or-30-03-1053" ref-type="bibr">17</xref>,<xref rid="b19-or-30-03-1053" ref-type="bibr">19</xref>). It has been proposed that amino acids 360&#x02013;370 of Top1 form a loop region, which contacts other loop regions (residues 417&#x02013;423, 496&#x02013;505 and 529&#x02013;538) to create a salt bridge and two non-covalent bonds between the cap region and the bottom lobe of the enzyme (<xref rid="b19-or-30-03-1053" ref-type="bibr">19</xref>). Several structural models have demonstrated that camptothecin derivatives mimic a DNA pair and inhibit the DNA religation activity of Top1 by stabilizing the covalent Top1-DNA complexes (<xref rid="b1-or-30-03-1053" ref-type="bibr">1</xref>,<xref rid="b20-or-30-03-1053" ref-type="bibr">20</xref>). Moreover, structural models have indicated that camptothecin derivatives interact with Arg364, Asp533 and Asn722 of Top1 (<xref rid="b17-or-30-03-1053" ref-type="bibr">17</xref>,<xref rid="b20-or-30-03-1053" ref-type="bibr">20</xref>). The newly identified Top1 mutations in this study were positioned in or near the residues that have been shown to be important for enzyme-DNA interactions or enzyme-drug interactions.</p><p>The camptothecin-resistant cell lines overexpressed MDR1 and BCRP (<xref rid="tI-or-30-03-1053" ref-type="table">Table I</xref>). The overexpression of ATP-binding cassette transporters is often responsible for the cellular resistance to anticancer drugs. Camptothecin derivatives and indolocarbazole Top1 inhibitors have been demonstrated to be effectively effluxed by BCRP, while camptothecin is a relatively poor substrate for MDR1 (<xref rid="b21-or-30-03-1053" ref-type="bibr">21</xref>&#x02013;<xref rid="b23-or-30-03-1053" ref-type="bibr">23</xref>). Verapamil and Ko143 could not enhance the effects of camptothecin on the highly resistant cells in terms of the growth rate or cell cycle progression (data not shown). The higher concentration of camptothecin plus verapamil or Ko143 could not trap covalent enzyme-DNA complexes by a band depletion assay in these cells (data not shown). The established cells in this study were ~15 to 150-fold resistant to the indolocarbazole derivative, J-107088 (<xref rid="f2-or-30-03-1053" ref-type="fig">Fig. 2</xref>). The exposure of cells to 5 &#x003bc;M of J-107088 plus 0.3 &#x003bc;M Ko143 caused the accumulation of SNRA23F and SNRA311E cells in the late S to G<sub>2</sub>/M phase. In the SNRD16F and SNRD38 cells, this combined exposure caused accumulation in the late S-G<sub>2</sub>/M phase, but the G0/1 population remained in these cells (<xref rid="f5-or-30-03-1053" ref-type="fig">Fig. 5</xref>). These data suggested that J-107088 effectively caused DNA damage in SNRA23F and SNRA311E cells compared with SNRD16F and SNRD38F cells, although the SNRA23 cells expressed more BCRP mRNA than SNRD38F. A Top1Gln412Arg mutation may confer further resistance to this indolocarbazole derivative. In the cytotoxicity assay, the SNRD16F and SNRD38F cells were slightly more resistant to J-107088 at higher concentrations compared with SNRA23F and SNRA311E cells (<xref rid="f2-or-30-03-1053" ref-type="fig">Fig. 2</xref>).</p><p>The DLDSNR6 cells have shown a loss of heterozygosity in the TOP1 gene and exhibited genomic instability due to homozygous mutations in the hMSH6 gene (<xref rid="b7-or-30-03-1053" ref-type="bibr">7</xref>). This background enabled us to establish the highly camptothecin-resistant cell lines that had three mutations in one allele of the TOP1 gene. To the best of our knowledge, such cell lines have not previously been reported. The Top1Gly717 mutation has been reported in camptothecin-resistant ovarian cancer cells (<xref rid="b24-or-30-03-1053" ref-type="bibr">24</xref>). A mutation corresponding to human Top1Glu421 was previously identified in camptothecin-producing plants, but it has not been identified in mammalian cells (<xref rid="b8-or-30-03-1053" ref-type="bibr">8</xref>). The camptothecin producing plants have three mutations in the TOP1 gene and mutations in residues sterically near the catalytic tyrosine in addition to the Glu421 mutation. Our newly established cell lines may be useful for understanding enzyme-drug interactions and the molecular evolution of drug resistance.</p></sec></body><back><ack><title>Acknowledgements</title><p>This study was supported by Japan Society for the Promotion of Science KAKENHI grant no. 24701011 (Y.A.) and was also supported by a grant from the Vehicle Racing Commemorative Foundation (Y.A.).</p></ack><ref-list><title>References</title><ref id="b1-or-30-03-1053"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staker</surname><given-names>BL</given-names></name><name><surname>Hjerrild</surname><given-names>K</given-names></name><name><surname>Feese</surname><given-names>MD</given-names></name><name><surname>Behnke</surname><given-names>CA</given-names></name><name><surname>Burgin</surname><given-names>AB</given-names></name><name><surname>Stewart</surname><given-names>L</given-names></name></person-group><article-title>The mechanism of topoisomerase I poisoning by a camptothecin analog</article-title><source>Proc Natl Acad Sci USA</source><volume>99</volume><fpage>15387</fpage><lpage>15392</lpage><year>2002</year><pub-id pub-id-type="pmid">12426403</pub-id></element-citation></ref><ref id="b2-or-30-03-1053"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pommier</surname><given-names>Y</given-names></name><name><surname>Cushman</surname><given-names>M</given-names></name></person-group><article-title>The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives</article-title><source>Mol Cancer Ther</source><volume>8</volume><fpage>1008</fpage><lpage>1014</lpage><year>2009</year><pub-id pub-id-type="pmid">19383846</pub-id></element-citation></ref><ref id="b3-or-30-03-1053"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;chez</surname><given-names>C</given-names></name><name><surname>M&#x000e9;dez</surname><given-names>C</given-names></name><name><surname>Salas</surname><given-names>JA</given-names></name></person-group><article-title>Indolocarbazole natural products: occurrence, biosynthesis, and biological activity</article-title><source>Nat Prod Rep</source><volume>23</volume><fpage>1007</fpage><lpage>1045</lpage><year>2006</year><pub-id pub-id-type="pmid">17119643</pub-id></element-citation></ref><ref id="b4-or-30-03-1053"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JC</given-names></name></person-group><article-title>Cellular roles of DNA topoisomerases: a molecular perspective</article-title><source>Nat Rev Mol Cell Biol</source><volume>3</volume><fpage>430</fpage><lpage>440</lpage><year>2002</year><pub-id pub-id-type="pmid">12042765</pub-id></element-citation></ref><ref id="b5-or-30-03-1053"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchand</surname><given-names>C</given-names></name><name><surname>Antony</surname><given-names>S</given-names></name><name><surname>Kohn</surname><given-names>KW</given-names></name><etal/></person-group><article-title>A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex</article-title><source>Mol Cancer Ther</source><volume>5</volume><fpage>287</fpage><lpage>295</lpage><year>2006</year><pub-id pub-id-type="pmid">16505102</pub-id></element-citation></ref><ref id="b6-or-30-03-1053"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urasaki</surname><given-names>Y</given-names></name><name><surname>Laco</surname><given-names>G</given-names></name><name><surname>Takebayashi</surname><given-names>Y</given-names></name><name><surname>Bailly</surname><given-names>C</given-names></name><name><surname>Kohlhagen</surname><given-names>G</given-names></name><name><surname>Pommier</surname><given-names>Y</given-names></name></person-group><article-title>Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site</article-title><source>Cancer Res</source><volume>61</volume><fpage>504</fpage><lpage>508</lpage><year>2001</year><pub-id pub-id-type="pmid">11212241</pub-id></element-citation></ref><ref id="b7-or-30-03-1053"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arakawa</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name></person-group><article-title>Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells</article-title><source>Mol Cancer Ther</source><volume>5</volume><fpage>502</fpage><lpage>508</lpage><year>2006</year><pub-id pub-id-type="pmid">16546964</pub-id></element-citation></ref><ref id="b8-or-30-03-1053"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirikantaramas</surname><given-names>S</given-names></name><name><surname>Yamazaki</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>K</given-names></name></person-group><article-title>Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plants</article-title><source>Proc Natl Acad Sci USA</source><volume>105</volume><fpage>6782</fpage><lpage>6786</lpage><year>2008</year><pub-id pub-id-type="pmid">18443285</pub-id></element-citation></ref><ref id="b9-or-30-03-1053"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasheed</surname><given-names>ZA</given-names></name><name><surname>Rubin</surname><given-names>EH</given-names></name></person-group><article-title>Mechanisms of resistance to topoisomerase I-targeting drugs</article-title><source>Oncogene</source><volume>22</volume><fpage>7296</fpage><lpage>7304</lpage><year>2003</year><pub-id pub-id-type="pmid">14576839</pub-id></element-citation></ref><ref id="b10-or-30-03-1053"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urasaki</surname><given-names>Y</given-names></name><name><surname>Laco</surname><given-names>GS</given-names></name><name><surname>Pourquier</surname><given-names>P</given-names></name><etal/></person-group><article-title>Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line</article-title><source>Cancer Res</source><volume>61</volume><fpage>1964</fpage><lpage>1969</lpage><year>2001</year><pub-id pub-id-type="pmid">11280753</pub-id></element-citation></ref><ref id="b11-or-30-03-1053"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonven</surname><given-names>BJ</given-names></name><name><surname>Gocke</surname><given-names>E</given-names></name><name><surname>Westergaard</surname><given-names>O</given-names></name></person-group><article-title>A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in Tetrahymena R-chromatin</article-title><source>Cell</source><volume>41</volume><fpage>541</fpage><lpage>551</lpage><year>1985</year><pub-id pub-id-type="pmid">2985282</pub-id></element-citation></ref><ref id="b12-or-30-03-1053"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>TR</given-names></name><name><surname>Dorotinsky</surname><given-names>CS</given-names></name><name><surname>McGuire</surname><given-names>LJ</given-names></name><name><surname>Macy</surname><given-names>ML</given-names></name><name><surname>Hay</surname><given-names>RJ</given-names></name></person-group><article-title>DLD-1 and HCT-15 cell lines derived separately from colorectal carcinomas have totally different chromosome changes but the same genetic origin</article-title><source>Cancer Genet Cytogenet</source><volume>81</volume><fpage>103</fpage><lpage>108</lpage><year>1995</year><pub-id pub-id-type="pmid">7621404</pub-id></element-citation></ref><ref id="b13-or-30-03-1053"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moisan</surname><given-names>F</given-names></name><name><surname>Longy</surname><given-names>M</given-names></name><name><surname>Robert</surname><given-names>J</given-names></name><name><surname>Le Morvan</surname><given-names>V</given-names></name></person-group><article-title>Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines</article-title><source>Br J Cancer</source><volume>95</volume><fpage>906</fpage><lpage>913</lpage><year>2006</year><pub-id pub-id-type="pmid">16983402</pub-id></element-citation></ref><ref id="b14-or-30-03-1053"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toyoda</surname><given-names>E</given-names></name><name><surname>Kurosawa</surname><given-names>A</given-names></name><name><surname>Fujii</surname><given-names>M</given-names></name><name><surname>Adachi</surname><given-names>N</given-names></name></person-group><article-title>Heterozygous disruption of the DNA topoisomerase I gene confers cellular resistance to camptothecin in human cells</article-title><source>Biol Pharm Bull</source><volume>32</volume><fpage>724</fpage><lpage>727</lpage><year>2009</year><pub-id pub-id-type="pmid">19336913</pub-id></element-citation></ref><ref id="b15-or-30-03-1053"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>ZH</given-names></name><name><surname>Player</surname><given-names>A</given-names></name><name><surname>Shankavaram</surname><given-names>U</given-names></name><etal/></person-group><article-title>Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses</article-title><source>Cancer Res</source><volume>67</volume><fpage>8752</fpage><lpage>8761</lpage><year>2007</year><pub-id pub-id-type="pmid">17875716</pub-id></element-citation></ref><ref id="b16-or-30-03-1053"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McClendon</surname><given-names>AK</given-names></name><name><surname>Rodriguez</surname><given-names>AC</given-names></name><name><surname>Osheroff</surname><given-names>N</given-names></name></person-group><article-title>Human topoisomerase II&#x003b1; rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks</article-title><source>J Biol Chem</source><volume>280</volume><fpage>39337</fpage><lpage>39345</lpage><year>2005</year><pub-id pub-id-type="pmid">16188892</pub-id></element-citation></ref><ref id="b17-or-30-03-1053"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redinbo</surname><given-names>MR</given-names></name><name><surname>Stewart</surname><given-names>L</given-names></name><name><surname>Kuhn</surname><given-names>P</given-names></name><name><surname>Champoux</surname><given-names>JJ</given-names></name><name><surname>Hol</surname><given-names>WG</given-names></name></person-group><article-title>Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA</article-title><source>Science</source><volume>279</volume><fpage>1504</fpage><lpage>1513</lpage><year>1998</year><pub-id pub-id-type="pmid">9488644</pub-id></element-citation></ref><ref id="b18-or-30-03-1053"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>L</given-names></name><name><surname>Redinbo</surname><given-names>MR</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Hol</surname><given-names>WG</given-names></name><name><surname>Champoux</surname><given-names>JJ</given-names></name></person-group><article-title>A model for the mechanism of human topoisomerase I</article-title><source>Science</source><volume>279</volume><fpage>1534</fpage><lpage>1541</lpage><year>1998</year><pub-id pub-id-type="pmid">9488652</pub-id></element-citation></ref><ref id="b19-or-30-03-1053"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chrencik</surname><given-names>JE</given-names></name><name><surname>Staker</surname><given-names>BL</given-names></name><name><surname>Burgin</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Mechanisms of camptothecin resistance by human topoisomerase I mutations</article-title><source>J Mol Biol</source><volume>339</volume><fpage>773</fpage><lpage>784</lpage><year>2004</year><pub-id pub-id-type="pmid">15165849</pub-id></element-citation></ref><ref id="b20-or-30-03-1053"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laco</surname><given-names>GS</given-names></name><name><surname>Collins</surname><given-names>JR</given-names></name><name><surname>Luke</surname><given-names>BT</given-names></name><etal/></person-group><article-title>Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model</article-title><source>Biochemistry</source><volume>41</volume><fpage>1428</fpage><lpage>1435</lpage><year>2002</year><pub-id pub-id-type="pmid">11814334</pub-id></element-citation></ref><ref id="b21-or-30-03-1053"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Ikegami</surname><given-names>Y</given-names></name><name><surname>Aida-Hyugaji</surname><given-names>S</given-names></name><name><surname>Sawada</surname><given-names>S</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name></person-group><article-title>Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer</article-title><source>Cancer Lett</source><volume>234</volume><fpage>81</fpage><lpage>89</lpage><year>2006</year><pub-id pub-id-type="pmid">16309825</pub-id></element-citation></ref><ref id="b22-or-30-03-1053"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komatani</surname><given-names>H</given-names></name><name><surname>Kotani</surname><given-names>H</given-names></name><name><surname>Hara</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure</article-title><source>Cancer Res</source><volume>61</volume><fpage>2827</fpage><lpage>2832</lpage><year>2001</year><pub-id pub-id-type="pmid">11306452</pub-id></element-citation></ref><ref id="b23-or-30-03-1053"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pommier</surname><given-names>Y</given-names></name></person-group><article-title>Topoisomerase I inhibitors: camptothecins and beyond</article-title><source>Nat Rev Cancer</source><volume>6</volume><fpage>789</fpage><lpage>802</lpage><year>2006</year><pub-id pub-id-type="pmid">16990856</pub-id></element-citation></ref><ref id="b24-or-30-03-1053"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LF</given-names></name><name><surname>Ting</surname><given-names>CY</given-names></name><name><surname>Lo</surname><given-names>CK</given-names></name><etal/></person-group><article-title>Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance</article-title><source>Cancer Res</source><volume>57</volume><fpage>1516</fpage><lpage>1522</lpage><year>1997</year><pub-id pub-id-type="pmid">9108454</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-or-30-03-1053" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Establishment of highly camptothecin-resistant DLD-1 sublines. (A) Schema of the generation of highly camptothecin-resistant DLD-1 cell subclones. (B) Cell growth assay. Each subline was cultured, and the viable cell number was counted by a trypan blue dye exclusion test. The values are expressed as means &#x000b1; standard deviation (SD). The experiment was performed in 3 different cultures.</p></caption><graphic xlink:href="OR-30-03-1053-g00"/></fig><fig id="f2-or-30-03-1053" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Cytotoxicity of topoisomerase I-targeting drugs. Cells were cultured for 96 h in the presence of the indicated camptothecin, SN-38 and J-107088 concentrations. Cell viability was measured by an MTS assay. The values are expressed as means &#x000b1; SD (n=3).</p></caption><graphic xlink:href="OR-30-03-1053-g01"/></fig><fig id="f3-or-30-03-1053" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Topoisomerase I (Top1) mutations in highly camptothecin-resistant DLD-1 sublines. Full-length Top1 cDNA was amplified by reverse transcription-polymerase chain reactions, from RNA that was extracted from each clone and sequenced. The SNRA311E cells had the same missense mutations as the SNRA23F cells (Gly365Ser and Gly717Arg). The SNRD38F cells had the same mutations as the SNRD16F cells (Gly365Ser, Gly717Arg and Gln421Arg).</p></caption><graphic xlink:href="OR-30-03-1053-g02"/></fig><fig id="f4-or-30-03-1053" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Characterization of the highly camptothecin-resistant cell lines. (A) Topoisomerase I (Top1) and topoisomerase 2&#x003b1; (Top2&#x003b1;) protein expression in resistant cell lines evaluated by western blotting. Coomassie brilliant blue (CBB) staining demonstrated equal protein loading. (B) Top1-mediated plasmid relaxation. Supercoiled pHOT1 plasmid was incubated for 60 min with the indicated amounts of nuclear extracts from DLD-1 and camptothecin-resistant sublines. Asterisk, sample without nuclear extract. SC, supercoiled DNA. REL, relaxed DNA.</p></caption><graphic xlink:href="OR-30-03-1053-g03"/></fig><fig id="f5-or-30-03-1053" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Cell cycle analysis of drug-treated cells. DLD-1 and camptothecin-resistant cell lines were either treated with vehicle alone, J-107088 (5 &#x003bc;M), J-107088 (5 &#x003bc;M) + verapamil (10 mM), or J-107088 (5 &#x003bc;M) + Ko143 (0.3 &#x003bc;M) for 48 h. A DNA histogram analysis was performed by flow cytometry. Representative histograms from at least 2 independent experiments are shown.</p></caption><graphic xlink:href="OR-30-03-1053-g04"/></fig><table-wrap id="tI-or-30-03-1053" orientation="portrait" position="float"><label>Table I</label><caption><p>qRT-PCR array analysis of ATP-binding cassette transporters.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1">Gene</th><th align="center" valign="bottom" rowspan="1" colspan="1">DLD-1</th><th align="center" valign="bottom" rowspan="1" colspan="1">DLDSNR6</th><th align="center" valign="bottom" rowspan="1" colspan="1">SNRA23F</th><th align="center" valign="bottom" rowspan="1" colspan="1">SNRA311E</th><th align="center" valign="bottom" rowspan="1" colspan="1">SNRD16F</th><th align="center" valign="bottom" rowspan="1" colspan="1">SNRD38F</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ABCA2</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">0.871</td><td align="right" valign="top" rowspan="1" colspan="1">0.871</td><td align="right" valign="top" rowspan="1" colspan="1">0.824</td><td align="right" valign="top" rowspan="1" colspan="1">1.602</td><td align="center" valign="top" rowspan="1" colspan="1">0.807</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABCB1</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">6.774</td><td align="right" valign="top" rowspan="1" colspan="1">11.314</td><td align="right" valign="top" rowspan="1" colspan="1">17.268</td><td align="right" valign="top" rowspan="1" colspan="1">12.295</td><td align="center" valign="top" rowspan="1" colspan="1">7.945</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABCB4</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">2.028</td><td align="right" valign="top" rowspan="1" colspan="1">2.990</td><td align="right" valign="top" rowspan="1" colspan="1">2.621</td><td align="right" valign="top" rowspan="1" colspan="1">1.505</td><td align="center" valign="top" rowspan="1" colspan="1">1.117</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABCC1</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">1.141</td><td align="right" valign="top" rowspan="1" colspan="1">1.087</td><td align="right" valign="top" rowspan="1" colspan="1">0.914</td><td align="right" valign="top" rowspan="1" colspan="1">0.927</td><td align="center" valign="top" rowspan="1" colspan="1">0.883</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABCC2</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">0.486</td><td align="right" valign="top" rowspan="1" colspan="1">0.156</td><td align="right" valign="top" rowspan="1" colspan="1">0.071</td><td align="right" valign="top" rowspan="1" colspan="1">0.620</td><td align="center" valign="top" rowspan="1" colspan="1">0.374</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABCC3</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">0.753</td><td align="right" valign="top" rowspan="1" colspan="1">0.901</td><td align="right" valign="top" rowspan="1" colspan="1">0.883</td><td align="right" valign="top" rowspan="1" colspan="1">0.835</td><td align="center" valign="top" rowspan="1" colspan="1">0.901</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABCC4</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">1.050</td><td align="right" valign="top" rowspan="1" colspan="1">0.801</td><td align="right" valign="top" rowspan="1" colspan="1">0.889</td><td align="right" valign="top" rowspan="1" colspan="1">0.914</td><td align="center" valign="top" rowspan="1" colspan="1">1.007</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABCC5</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">1.035</td><td align="right" valign="top" rowspan="1" colspan="1">1.173</td><td align="right" valign="top" rowspan="1" colspan="1">1.240</td><td align="right" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">0.841</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABCC6</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">1.338</td><td align="right" valign="top" rowspan="1" colspan="1">2.868</td><td align="right" valign="top" rowspan="1" colspan="1">3.364</td><td align="right" valign="top" rowspan="1" colspan="1">3.227</td><td align="center" valign="top" rowspan="1" colspan="1">2.445</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABCC10</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">1.548</td><td align="right" valign="top" rowspan="1" colspan="1">2.085</td><td align="right" valign="top" rowspan="1" colspan="1">2.532</td><td align="right" valign="top" rowspan="1" colspan="1">1.753</td><td align="center" valign="top" rowspan="1" colspan="1">2.129</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABCC11</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">0.940</td><td align="right" valign="top" rowspan="1" colspan="1">0.274</td><td align="right" valign="top" rowspan="1" colspan="1">0.406</td><td align="right" valign="top" rowspan="1" colspan="1">0.339</td><td align="center" valign="top" rowspan="1" colspan="1">0.412</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABCG2</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td><td align="center" valign="top" rowspan="1" colspan="1">3.031</td><td align="right" valign="top" rowspan="1" colspan="1">6.105</td><td align="right" valign="top" rowspan="1" colspan="1">2.497</td><td align="right" valign="top" rowspan="1" colspan="1">9.580</td><td align="center" valign="top" rowspan="1" colspan="1">4.199</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-or-30-03-1053"><p>qRT-PCR, quantitative reverse transcription-polymerase chain reaction. Relative expression of ATP-binding cassette transporters between the parental DLD-1 and the resistant sublines. &#x00394;&#x00394;Ct values were converted to fold-change.</p></fn></table-wrap-foot></table-wrap></floats-group></article>